Investors
Company Overview
AXIM Biotechnologies (OTC: AXIM) is an international healthcare solutions company targeting ocular biomarkers. AXIM Eye is working with two highly specialized Point-of-Care (POC) lab testing solutions designed specifically to assist eye-care physicians in detecting and quantifying biomarkers associated with aqueous deficient dry eye disease and non-specific allergic conjunctivitis.
Investor Presentation
Email Alerts
Stay informed and receive company updates straight to your inbox
Recent News
AXIM Biotechnologies, Inc. and Medical Marijuana, Inc. Enter into Strategic Alliance to Research and Develop Applications and Uses of Patent for Water Soluble Cannabinoids
SAN DIEGO, CA - (NewMediaWire) - January 29, 2026 - AXIM Biotechnologies, Inc. (OTC: AXIM) (the "Company") today announced a strategic alliance with Medical Marijuana, Inc. (OTC: MJNA) intended to research and develop applications and uses for AXIM's patent for water...
AXIM Biotechnologies Engages 624 Advisors, owned and managed by Dr. Alan J. Touch, Innovator and Global Regulatory Leader, as Chief Medical & Regulatory Affairs Advisor
San Diego, CA — Jan 20 2026 — AXIM Biotechnologies, Inc. (“AXIM” or the “Company”), a diagnostic and biotechnology company advancing clinically validated solutions for ocular and inflammatory diseases, today announced the engagement of 624 Advisors, which is owned...
AXIM Biotechnologies, Inc. Announces Exclusive Distribution Agreement with VisionPlus Corp. for TearScan® Lactoferrin and IgE Diagnostic Tests in South Korea
San Diego, CA — October 23, 2025 — AXIM Biotechnologies, Inc. (“AXIM”), a leader in rapid, point-of-care ocular diagnostics, today announced it has entered into an exclusive distribution agreement with VisionPlus Corp. (“VisionPlus”) to market and distribute...
